CN109125706A - A kind of peptide composition for being effectively improved acne and repairing skin lesion - Google Patents
A kind of peptide composition for being effectively improved acne and repairing skin lesion Download PDFInfo
- Publication number
- CN109125706A CN109125706A CN201811097698.8A CN201811097698A CN109125706A CN 109125706 A CN109125706 A CN 109125706A CN 201811097698 A CN201811097698 A CN 201811097698A CN 109125706 A CN109125706 A CN 109125706A
- Authority
- CN
- China
- Prior art keywords
- acne
- polypeptide
- composition
- mass concentration
- peptide composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 83
- 206010000496 acne Diseases 0.000 title claims abstract description 83
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 206010040882 skin lesion Diseases 0.000 title claims abstract description 17
- 231100000444 skin lesion Toxicity 0.000 title claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 37
- 229920001184 polypeptide Polymers 0.000 claims abstract description 36
- 102000008186 Collagen Human genes 0.000 claims abstract description 17
- 108010035532 Collagen Proteins 0.000 claims abstract description 17
- 206010061218 Inflammation Diseases 0.000 claims abstract description 17
- 229920001436 collagen Polymers 0.000 claims abstract description 17
- 230000004054 inflammatory process Effects 0.000 claims abstract description 15
- 230000008439 repair process Effects 0.000 claims abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 8
- 230000008929 regeneration Effects 0.000 claims abstract description 8
- 238000011069 regeneration method Methods 0.000 claims abstract description 8
- 102000011782 Keratins Human genes 0.000 claims abstract description 7
- 108010076876 Keratins Proteins 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- -1 myristoyl hexapeptide -5 Chemical compound 0.000 claims description 10
- 108010030856 phenylalanyl-glycyl-valyl-statyl-alanyl-phenylalanine methyl ester Proteins 0.000 claims description 10
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 claims description 9
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 5
- 229920002498 Beta-glucan Polymers 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 229940031098 ethanolamine Drugs 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 1
- 241000186427 Cutibacterium acnes Species 0.000 abstract description 18
- 229940055019 propionibacterium acne Drugs 0.000 abstract description 18
- 231100000241 scar Toxicity 0.000 abstract description 16
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 13
- 230000012010 growth Effects 0.000 abstract description 8
- 238000009395 breeding Methods 0.000 abstract description 5
- 230000001488 breeding effect Effects 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 206010030113 Oedema Diseases 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 3
- 230000003014 reinforcing effect Effects 0.000 abstract description 3
- 210000001339 epidermal cell Anatomy 0.000 abstract description 2
- 230000035800 maturation Effects 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 30
- 238000012360 testing method Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 102000004890 Interleukin-8 Human genes 0.000 description 12
- 108090001007 Interleukin-8 Proteins 0.000 description 12
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 12
- 229940096397 interleukin-8 Drugs 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 229960001727 tretinoin Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000003255 anti-acne Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
- 229960002591 hydroxyproline Drugs 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000002647 laser therapy Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000002374 sebum Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000002280 anti-androgenic effect Effects 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000007872 degassing Methods 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000011017 operating method Methods 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 2
- 101710200814 Melanotropin alpha Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 206010048865 Hypoacusis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YAVVGPBYBUYPSR-UHFFFAOYSA-N benzene;oxygen Chemical compound [O].C1=CC=CC=C1 YAVVGPBYBUYPSR-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention discloses a kind of peptide composition for being effectively improved acne and repairing skin lesion, and the composition includes the polypeptide with antibacterial action, then adds the polypeptide for inhibiting inflammatory reaction and/or promote collagen and keratin regeneration, the polypeptide for repairing acne print.Peptide composition of the invention can inhibit the growth and breeding of propionibacterium acnes, staphylococcus aureus, inhibit inflammatory reaction, prevent oedema and red capillary, increase the synthesis of skin corium collagen, promote the regeneration and reinforcing of dermoepidermal connection (DEJ) plot structure tissue, promote the differentiation and maturation of epidermal cell, potent reparation acne print acne scar, to achieve the purpose that be effectively improved acne and repair skin lesion.
Description
Technical field
The invention belongs to biomedical polypeptide drugs technical fields, provide a kind of for being effectively improved acne and reparation
The peptide composition of skin lesion.
Background technique
Acne (acne) is a kind of common chronic inflammatory skin for betiding pilosebaceous follicle, be mainly in face and
The sebaceous glands such as chest and back position abundant, shows as acne, papule, useless fellow, tubercle and tumour etc., can lead to permanent scar.
The whelk often said also belongs to acne.
Acne can be caused by inside and outside many factors, and pathogenesis is mainly led with hypersteatosis, pilosebaceous follicle
The factors such as blockage, bacterium infection and inflammatory reaction are closely related.Pressure is excessive, the regular disorder of daily life system, endocrine disorder
Deng that all sebum secretion can be caused to increase, especially puberty androgen secretion is vigorous, can promote a large amount of greases of smegma, together
When influence pilosebaceous duct dyskeratosis, and then block pilosebaceous follicle so that sebum is difficult to be discharged.A large amount of sebums without
Method is normally discharged, and forms acne, leads to partial closure, provide good condition for the growth and breeding of propionibacterium acnes.Cuo
Sore Propionibacterium is the normal bacterial parasite of skin, is a kind of Gram-positive anaerobic bacillus(cillus anaerobicus), harmless under normal circumstances.When
After pilosebaceous follicle blocking, a large amount of sebum accumulations, while local anaerobic environment is built, propionibacterium acnes are able to a large amount of numerous
It grows.They generate a large amount of free fatty acid by decomposing saturated fatty acid, and then skin is stimulated to be inflamed reaction, simultaneously
Chemotactic inflammatory cell and medium stimulate inflammatory cytokine such as interleukin 8 (IL-8), tumor necrosis factor-alpha (TNF-α)
Release, induce and aggravate inflammatory reaction.Inflammatory reaction aggravates, and acne can further evolve into various inflammatory skin lesions, shows
For red papule, useless fellow, tubercle or tumour.
Propionibacterium acnes are the most important pathogenic microorganisms for causing acne.In addition, staphylococcus aureus is also to make
At the important pathogenic bacteria of acne infection.Staphylococcus aureus also exists in skin, pore, bronchia mucosal of healthy population etc.
Position belongs to conditioned pathogen, causes the generation for leading to acne, erythema after acne infection.With the exacerbation of infection, it may appear that purulence
Pouch-type acne, causes serious harm to skin.
Bacterium infection and inflammatory reaction etc. cause skin histology impaired, form acne print.When acne causes skin injury serious,
Depth and corium cause skin corium collagen to be lost, and skin texture collapses or Large Area Skin damage layer, and skin, which cannot regenerate, to be repaired
It is multiple, cause face uneven, is formed permanent acne scar, seriously affects beauty, cause great psychological pressure to patient
And mental suffering, seriously affect quality of life.
Currently, mainly having western medicine, Chinese medicine treatment, laser therapy etc. for the treatment method of acne.
Common drug includes antiandrogens, antibiotic, Tretinoin etc. in western medicine.Antiandrogens
It is main to be generated by reducing androgen, prevent testosterone in conjunction with the androgen receptor on sebaceous glands etc., to inhibit sebum secretion
To achieve the purpose that treat acne, if Cimetidine can inhibit adrenal gland to generate androgen, clinically can be used for treating
Acne, but the drug has the function of very strong gastric acid secretion inhibiting simultaneously, as prolonged application will lead to patient's anorexia or even stomach
Sour diacrisis.In addition, all unavoidable side effect of antiandrogens is to will lead to dyssecretosis.Antibiotic is for example red mould
Element, chloramphenicol, tetracycline, metronidazole etc. are controlled by killing the pathogenic bacteria such as propionibacterium acnes and staphylococcus aureus with playing
Treat the effect of acne.But abuse of antibiotics is easy to cause bacterial resistance, and while killing pathogenic bacteria, can to skin other
Bacterium impact, it is possible to destroy the normal flora of skin.Topical Retinoids can also reduce acne propionic acid to a certain extent
The Microflora of bacillus alleviates the blocking of sebaceous glands, also has anti-inflammatory effect, therefore is clinically also the common for the treatment of acne
One of drug.But Tretinoin is very big to the stimulation of skin, causes skin drying, furfur, erythema, itch, burn feeling etc. occur existing
As, in some instances it may even be possible to acne aggravates phenomenon, and many patients can not often be resistant to.
Clinically mainly based on clearing heat and detoxicating, part Chinese medicine also has propionibacterium acnes certain Chinese medicine treatment acne
Inhibiting effect, but often the course for the treatment of is longer for Chinese medicine treatment acne, and the mechanism of action of Chinese medicine need to be illustrated, and these are all limited
The application of Chinese medicine.
Laser therapy acne is the laser using specific wavelength, kills propionibacterium acnes, staphylococcus aureus etc. and causes
Germ, while skin being stimulated to generate collagen, acne print is repaired, to achieve the purpose that anti-acne is dispelled scar.But laser therapy is avoided
Disease is more, have on the people of the photosensitizers such as used tetracycline, Tretinoin, face inflammation person etc. cannot using laser therapy acne,
And the skin after laser treatment is more fragile, is easy infection, therefore laser therapy should be used with caution.
In addition to the methods of drug therapy, laser therapy, there are also the cosmetics of many treatment acnes on the market.These products are big
It is claimed to anti-inflammation and sterilization in a short time, quick anti-acne, in fact mostly is to be added to the cosmetics disablings such as hormone, chemical bacteriostatic agent more
Ingredient is used for a long time these cosmetics and is tantamount to drink poison to quench thirst, causes skin allergy, leads to propionibacterium acnes, golden yellow Portugal
Grape coccus etc. generates drug resistance, is delayed best occasion for the treatment so that the course of disease of acne is more complicated and it is tight to eventually lead to skin histology
It is damaged again, occurs permanent scar on the face, irredeemable injury is caused to patient.
In conclusion this field be badly in need of one kind can safely and effectively, technical effect it is good, can make up for it prior art defect
Skin-protection product or curable product.
Summary of the invention
The purpose of the present invention is to provide a kind of peptide compositions for being effectively improved acne and repairing skin lesion.Polypeptide is as people
The Physiological effect substance that weight is wanted has a variety of physiological activity, and safe to the human body non-stimulated.Pass through the combination of not homopolypeptide
It plays a role in different target spots, improve acne in all directions and repairs skin lesion.
To achieve the above object, one is formd according to skin physiology biochemical characteristic and the pathogenesis of acne, the present inventor
Cover anti-acne and desalinate acne print acne scar scheme, comprising the polypeptide with antibacterial action, then add inhibit inflammatory reaction polypeptide and/
Or promote collagen and keratin regeneration, the polypeptide for repairing acne print.
Wherein, the polypeptide with antibacterial action can be one or more kinds of selected from following polypeptide, including but not limited to meat
Myristoyl hexapeptide -5, myristoyl hexapeptide -23, tetrapeptide -1；
The polypeptide of inflammatory reaction is inhibited to can be one or more kinds of selected from following polypeptide, including but not limited to palmityl three
Peptide -8；
Collagen and the polypeptide of keratin regeneration, reparation acne print is promoted to can be one or more kinds of selected from following more
Peptide, including but not limited to hexapeptide -9, heptapeptide -6；
Above each polypeptide moiety mass concentration is 0.0001%-5%.
Peptide composition of the present invention can be myristoyl hexapeptide -5 and palmityl tripeptides -8 combine, each polypeptide moiety
Mass concentration is 0.0001%-5%；
Peptide composition of the present invention can be myristoyl hexapeptide -5 and hexapeptide -9 combines, and each polypeptide moiety quality is dense
Degree is 0.0001%-5%；
Peptide composition of the present invention can be myristoyl hexapeptide -5, palmityl tripeptides -8 and hexapeptide -9 and combine, respectively
Polypeptide moiety mass concentration is 0.0001%-5%.
The present invention can add the other compositions enhanced human immunity, preferably beta glucan；Moisturizer is added, it is preferably sweet
Oil, butanediol；The mass concentration of the above components is 0.001%-5% (w/w).
The present invention includes thickener, preferably Acritamer 940, and mass concentration range is 0.25%-0.5%.
The present invention includes preservative, preferably Phenoxyethanol, and mass concentration range is 0.2%-0.5%.
The present invention includes pH adjusting agent, and the pH adjusting agent is selected from: triethanolamine, sodium bicarbonate, saleratus, preferably three
Ethanol amine；Composition pH range is 3.0~8.0, preferably 5.0-7.0.
The present invention is mainly to prepare the skin-protection product or curable product of external preparation for skin using composite polypeptide composition, can be with
Applied to the growth and breeding for inhibiting propionibacterium acnes, staphylococcus aureus, inhibits inflammatory reaction, prevent oedema and red blood
Silk increases the synthesis of skin corium collagen, promotes the regeneration and reinforcing of dermoepidermal connection (DEJ) plot structure tissue, promotes
The differentiation and maturation of epidermal cell, potent reparation acne print acne scar, to achieve the purpose that be effectively improved acne and repair skin lesion.
Various dosage forms can be made in peptide composition of the invention, as development dosage form mainly has emulsion, cream, gel
Deng.
Acquired beneficial effect includes: the present invention compared with the existing technology
The present invention has found in clinical test, some polypeptides with antibacterial action, such as myristoyl hexapeptide -5, Ke Yigao
Effect inhibits the growth and breeding of propionibacterium acnes, staphylococcus aureus, alleviates inflammation, effectively prevents and improve acne, and
Antibacterial peptide can prevent bacterium from generating drug resistance, more safe and effective compared to chemical bacteriostatic agent.Some inhibition Neurogenic inflammatories are anti-
The polypeptide answered, such as palmityl tripeptides -8, the release for the proinflammatory factor interleukin 8 (IL-8) that can effectively inhibit UVB to induce,
It can inhibit the prior step of cascade of response of inflammation, effectively prevent and mitigate the inflammation and symptom caused by chemical stimulation,
The generation of tumor necrosis factor-alpha (TNF-α) can be interfered, the neurodermatitiss symptom such as oedema and red capillary is prevented, prevents and change
Kind acne print.It is some to promote collagen and the polypeptide of keratin regeneration, reparation acne print that increase skin corium glue such as hexapeptide -9
The synthesis of former albumen increases the quantity of Laminin ELISA-V, Integrin, promotes dermoepidermal connection (DEJ) plot structure tissue
Regeneration and reinforcing, promote keratinocyte differentiation, and keratin synthesis recombinates complete table cortex to repair wound.Examination of the invention
It tests data to show, these peptide compositions are by acting on different skin target spot, to more effectively improve acne and repair skin
Damage.
Detailed description of the invention
The different dosing group IL-8 burst size of Fig. 1 UVB induction
Specific embodiment
For a better understanding of the present invention, invention is described in detail below with reference to embodiment and attached drawing, but not only
It is limited to embodiment below.
Embodiment 1
Anti-acne jelly formula
Preparation method:
In the case where quick stirring, the Acritamer 940 of formula ratio is slowly added into portions of de-ionized water, is sufficiently divided
It dissipates uniformly, heating makes to be completely dissolved.
Remaining deionized water is heated to 35 DEG C or so, warm water dissolves palmityl tripeptides -8, continuously adds myristoyl six
Peptide -5, glycerol, butanediol, beta glucan, Phenoxyethanol, stirring make it completely dissolved.
It by both above-mentioned mixing, stirs evenly, triethanolamine is added and neutralizes, degassing to product bubble-free.
Embodiment 2
Anti-acne jelly formula
Preparation method:
In the case where quick stirring, the Acritamer 940 of formula ratio is slowly added into portions of de-ionized water, is sufficiently divided
It dissipates uniformly, heating makes to be completely dissolved.
Into remaining deionized water, myristoyl hexapeptide -5, hexapeptide -9, glycerol, butanediol, beta glucan, benzene oxygen is added
Ethyl alcohol, stirring make it completely dissolved.
It by both above-mentioned mixing, stirs evenly, triethanolamine is added and neutralizes, degassing to product bubble-free.
Embodiment 3
Anti-acne jelly prescription
Preparation method:
In the case where quick stirring, the Acritamer 940 of formula ratio is slowly added into portions of de-ionized water, is sufficiently divided
It dissipates uniformly, heating makes to be completely dissolved.
Remaining deionized water is heated to 35 DEG C or so, warm water dissolves palmityl tripeptides -8, continuously adds myristoyl six
Peptide -5, hexapeptide -9, glycerol, butanediol, beta glucan, Phenoxyethanol, stirring make it completely dissolved.
It by both above-mentioned mixing, stirs evenly, triethanolamine is added and neutralizes, degassing to product bubble-free.
4 minimal inhibitory concentration of embodiment (MIC) measurement test
4.1 materials and instrument
Nutrient broth medium (peptone, beef extract, sodium chloride, distilled water), (tryptone physiology salt is water-soluble for dilution
Liquid TPS: tryptone, sodium chloride), agar, embodiment 3 prepare sample, erythromycin, ethyl alcohol, superclean bench, high pressure sterilization
Device, constant incubator, suction pipe, test tube
Bacterium is used in 4.2 tests
Propionibacterium acnes (Propionibacterium acnes) (ATCC 11827), staphylococcus aureus
(Staphylococcus aureus)(ATCC 6538)
4.3 detection foundations and method
" disinfection technology standard " (Ministry of Public Health's version in 2002) second part -2.1.8.4, nutrient broth dilution method
4.4 operating procedure
Propionibacterium acnes take the 3rd generation of strain~the 14th generation nutrient agar inclined-plane fresh after passage is brought back to life
Culture is drawn 3.0mL~5.0mL dilution with 5.0mL suction pipe and is added in slant tube, and pressure-vaccum, washes lower lawn repeatedly.With
Afterwards, washing lotion is moved in another sterile test tube with 5.0mL suction pipe, (oscillation) 20s is mixed with motorized agitator, so that bacterial suspension
Uniformly.Bacteria suspension made of preliminary, first with the bigness scale of bacterial concentration nephelometry, it contains bacteria concentration, then extremely with diluted
The required concentration used, it is ready-to-use.
By 3 sample of embodiment with sterile distilled water do to be serially diluted into again various concentration by test solution, take each dilution
It is added to by test solution 2.5mL in the test tube of the double concentration nutrient broth containing 2.5mL.Taking 0.1mL bacteria containing amount is about 108CFU/mL bacterium
Suspension is successively inoculated in the test tube of the nutrient broth of 3 peptide composition of embodiment containing various concentration from low concentration to high concentration
In, as test group sample.In kind by bacterial suspension inoculation in the test tube of the nutrient broth without peptide composition, make
For positive controls sample.2 test tubes containing nutrient broth are taken, as negative control group sample.Test group sample, the positive is right
It is placed in 37 DEG C of incubators according to group sample and negative control group sample, cultivates 48h, observe result.
Test should be carried out viable bacteria culture with bacteria suspension in test to count, activity should be 5 × 105CFU/mL~5
×106CFU/mL。
The MIC value of staphylococcus aureus is acted on same operating procedure measurement peptide composition.
4.5 test result
MIC judgment basis: when positive control pipe has bacterial growth (muddiness), negative control pipe asepsis growth (transparent) is tried
Testing with the activity of bacteria suspension is 5 × 105CFU/mL~5 × 106When CFU/mL, the highest dilution of test group asepsis growth
Corresponding peptide composition concentration is the sample to the MIC of tested bacterium.MIC is smaller, then antibacterial activity is stronger.
The peptide composition of various concentration to the growth inhibition effects of propionibacterium acnes, staphylococcus aureus respectively such as
Shown in lower:
As can be seen from the results, the peptide composition of embodiment 3 is 31ppm (1000ppm/32) to the MIC of propionibacterium acnes,
That is 31 μ g/mL, and the erythromycin detected through same procedure is 64 μ g/mL to the MIC of propionibacterium acnes, embodiment 3
Peptide composition is just shown at low concentrations to the good growth inhibition effect of propionibacterium acnes.Similarly, embodiment 3 is more
Peptide combinations are 31 μ g/mL to the MIC of staphylococcus aureus, are also shown at low concentrations good to staphylococcus aureus
Growth inhibition effect.It can to sum up obtain, the peptide composition of embodiment 3 can efficiently inhibit propionibacterium acnes, golden yellow
The growth and breeding of the pathogenic bacteria such as staphylococcus, and it is safe and non-toxic, bacterium is not easily led to and generates drug resistance, therefore is expected to substitution and is passed
Antibiotic of uniting is used for the antibacterial therapy of acne.
5 anti-inflammation test of embodiment
5.1 materials and instrument
NCTC cell (keratinocyte from normal human subject skin), DMEM culture medium, fetal calf serum, concentration 10-
α-the MSH of 11M, the sample of embodiment 1, embodiment 3, full-automatic microplate reader, human interleukin -8 (IL-8) ELISA are (enzyme-linked
Immunosorbent assay) kit
5.2 test method
DMEM culture medium (containing 5% fetal calf serum) is added in NCTC cell, is placed in containing 5%CO2, humidity 95%, constant temperature 37
DEG C carbon dioxide incubator in cultivate, replace culture solution after cultivating 48h, cover with culture bottle to cell, taking-up discards culture solution,
Digestive juice about 3mL is added, to be limited covered with bottom of bottle, after about 2-3 minutes, when discovery cytoplasm retraction adds after space between cells increases
Enter DMEM culture medium and terminate reaction, and is prepared into single cell suspension.
NCTC cell irradiates (230mJ/cm through UVB2), in sample and PBS containing α-MSH, embodiment 1, embodiment 3
Culture medium in cultivate respectively for 24 hours.With PBS (PH7.2-7.4) diluting cells suspension.By multigelation, make cytoclasis simultaneously
Release intracellular composition.It is spare carefully to collect supernatant for centrifugation.
With IL-8ELISA kit, operating procedure to specifications, sample-adding, incubate, washing, it is enzyme, incubate, washing,
Colour developing after terminating reaction, measures each hole OD value (OD value) under 450nm wavelength with microplate reader, is calculated by standard curve
The content of IL-8 in sample.
5.3 test result
Peptide composition inhibits the test result of the IL-8 release of UVB induction to see the table below 1 and Fig. 1:
The different dosing group IL-8 burst size of 1 UVB of table induction
The different dosing group IL-8 burst size of Fig. 1 UVB induction
By graph results it is found that peptide composition has effects that be similar to α-MSH, it can reduce and be drawn by UVB irradiation
The release of the inflammatory mediator IL-8 risen, so that Neurogenic inflammatory be inhibited to react.Relative to the peptide composition of embodiment 1, pass through
After the different polypeptide organic assembling of more mechanism of action, the peptide composition in embodiment 4 inhibits the effect of IL-8 release more
It is excellent.
The test that embodiment 6 promotes collagen to generate
6.1 animal experiment
Healthy 10 weeks nude mices, male, weight 20g or so.
6.2 reagents and instrument
Peptide composition, the spectrophotometer of skin hydroxyproline determination kit, embodiment 2 and embodiment 3.
6.3 test method
The hard of hearing peptide composition for smearing embodiment 2, embodiment 3 respectively on the right side of nude mice, each primary smearing daily morning and evening,
Medication 1g.Left side not medication is as a control group.Under the conditions of cleaning, ventilation, drying, 22 ± 2 DEG C of room temperature, identical forage feed.
5 are respectively taken after medication 30 days, are put to death, are taken its drug effect position and opposite side corresponding site skin.
It weighs 45mg (weight in wet base) tissue in the balance to be put into clean tube, hydrolyzate in hydroxyproline determination kit is added
1mL is mixed.It covers boiling water bath and hydrolyzes 20min, mixed once every 10min, to make hydrolysis more abundant.Test tube is taken out, it is cold
But it drips, shakes up toward the indicator 1 that kit is added in each pipe after.Solution A 1mL tune pH in kit is added, is shaken up.Then it uses
Sample injector draws the second liquid for adjusting pH, is added dropwise in each test tube, until seeing that the indicator in each pipe becomes yellow green.It is added and steams
It is mixed after distilled water to 10mL.It is mixed after taking the hydrolyzate of 3mL that 20-30mg active carbon is added, 3500rpm is centrifuged 10min, takes supernatant
1mL。
Take clean tube that 5 μ g/mL Standard Applying Solution 1mL are added as standard pipe.It is mixed after reagent 1 is added into each pipe,
10min is stood, reagent 2 is added, mixes and stands 5min, reagent 3 is added, mixes 60 DEG C of water-bath 15min, 3500rpm after cooling
It is centrifuged 10min, supernatant is taken to measure absorbance value under 550nm wavelength.
The measurement of 6.4 results and analysis
Hydroxyproline is a kind of peculiar amino acid of collagen, often containing with the content conversion collagen of hydroxyproline
Amount.Using the content of spectrophotometry measurement hydroxyproline, by in collagen 14% hydroxyproline conversion mouse skin
Collagen content, test result is as shown in table 2.
The influence that 2 peptide composition of table generates collagen in mouse skin
Note: * * indicates peptide composition group significant difference compared to the blank group, p < 0.01.
From the data in the table, compared with blank control group, peptide composition administration group can dramatically increase glue in skin
The content of former albumen is greatly promoted the generation of collagen in skin by the different role mechanism of polypeptide.
Embodiment 7 improves acne and repairs the test of skin lesion
7.1 test method
The volunteer of 90 healths is selected, the range of age 25-30 years old, these volunteer's faces all suffered from acne, and
Acne print or acne scar at all at least one on the face, clinical manifestation be old acne more after, local skin is impaired and there are shapes on surface
Shape is different, the different recess of the depth, and some is with pigmentation.
These volunteers are randomly divided into 3 groups, use the production of 3 peptide composition of embodiment respectively after clean face sooner or later daily
Product, Tretinoin emulsifiable paste, placebo are used continuously 8 weeks, sooner or later each to smear once, use respectively at acne affected part and acne print acne scar
Medicine.The adverse reaction situation occurred in the nbjective symptom and therapeutic process of record patient in detail before and after treatment is investigated each group and is produced
The acne-removing of product and the effect repaired skin lesion, desalinate acne print acne scar.
7.2 index of assessment of curative effect
The anti-acne effect of product is evaluated according to following standard:
(1) cure: acne subsides and does not leave obvious acne print acne scar；
(2) effective: acne recession area is greater than 60%；
(3) effectively: acne recession area is between 30%-60%；
(4) invalid: acne is without significant change or recession area less than 30%.
Total effective rate=(curing number of cases+effective number of cases+effective number of cases)/total number of cases × 100%
7.3 test result
After treating 8 weeks, compare the total effective rate situation of each group, placebo total effective rate is 6.67%, Tretinoin administration group
Total effective rate is 83.33%, and 3 peptide composition administration group total effective rate of embodiment is 80.00%.The therapeutic evaluation situation of each group
It is shown in Table 3.The result shows that the peptide composition of embodiment 3 can effectively improve acne relative to placebo, have and dimension A
The comparable curative effect of acid, but Tretinoin is larger to the irritation of patient skin, during medication most of patients occur red swelling of the skin, shouting pain,
The adverse reactions such as burn feeling seriously affect patient medication compliance, and peptide composition is safe to the human body non-stimulated, shows to compare
The better compliance of Tretinoin.Therefore, the peptide composition product of embodiment 4 is expected to substitution Tretinoin for treating acne.
Therapeutic evaluation situation after 3 each group volunteer of table treatment 8 weeks
Record the case where each group repairs skin lesion, desalination acne print acne scar respectively after treating 4 weeks, 8 weeks, the results are shown in Table 4.
The result from table is it is found that 3 peptide composition administration group of embodiment has significantly more repaired skin lesion, elimination color than Tretinoin administration group
Spot desalinates acne print acne scar, enables skin more smooth, full.
In addition, with the extension of use time, the product of peptide composition group repairs skin lesion, light after using 8 weeks
The effect for changing acne print acne scar is obviously better than the effect after using 4 weeks, and active peptides nonhazardous safe to the human body, mild stingless
Swash, can be used for a long time.
In conclusion the polypeptide of variant mechanism of action, through organic assembling, collaboration plays antibacterial, anti-inflammatory, repairs skin lesion
Effect, the resultant effect that scheme has better anti-acne, desalinates acne print acne scar compared with the existing technology.
4 each group of table repairs the case where skin lesion, desalination acne print acne scar
The above content is the further details of explanations for combining specific preferred embodiment to be the present invention, but not
Indicate that specific implementation of the invention is limited to these explanations.For those skilled in the art,
Under the premise of not departing from present inventive concept, several simple deductions or replacement can also be made, is regarded as belonging to of the invention
Protection scope.
Claims (10)
1. it is a kind of be effectively improved acne and repair skin lesion peptide composition, characterized by comprising:
(1) polypeptide with antibacterial action is selected from one or more following polypeptides, including but not limited to myristoyl hexapeptide -5, meat
Myristoyl hexapeptide -23, tetrapeptide -1；
(2) there is the polypeptide for inhibiting inflammatory reaction, promote collagen and one of keratin regeneration, the polypeptide for repairing acne print
Or two kinds, the polypeptide for inhibiting inflammatory reaction is selected from one or more following polypeptides, including but not limited to palmityl tripeptides -8；
It is described that collagen and the polypeptide of keratin regeneration, reparation acne print is promoted to be selected from one or more following polypeptides including but unlimited
In hexapeptide -9, heptapeptide -6；
Wherein above each polypeptide moiety mass concentration is 0.0001%-5%.
2. composition according to claim 1, which is characterized in that the peptide composition can for myristoyl hexapeptide -5,
Palmityl tripeptides -8 combine, and each polypeptide moiety mass concentration is 0.0001%-5%.
3. composition according to claim 1, which is characterized in that the peptide composition can for myristoyl hexapeptide -5,
Hexapeptide -9 combines, and each polypeptide moiety mass concentration is 0.0001%-5%.
4. composition according to claim 1, which is characterized in that the peptide composition can for myristoyl hexapeptide -5,
Palmityl tripeptides -8 and hexapeptide -9 combine, and each polypeptide moiety mass concentration is 0.0001%-5%.
5. composition described in any claim by claim 1-4, which is characterized in that enhancing human immunity can be added
The other compositions of power, preferably beta glucan, mass concentration range are 0.001%-5%.
6. composition described in any claim by claim 1-4, which is characterized in that thickener can be added, preferably
Acritamer 940, mass concentration range are 0.25%-0.5%.
7. composition described in any claim by claim 1-4, which is characterized in that moisturizer can be added, preferably
Glycerol, butanediol, mass concentration range are 0.001%-5%.
8. by composition described in claim 1-4 any claim, which is characterized in that preservative, preferably benzene can be added
Oxyethanol, mass concentration range are 0.2%-0.5%.
9. by composition described in claim 1-4 any claim, which is characterized in that further include pH adjusting agent, be selected from three
Ethanol amine, sodium bicarbonate, saleratus, preferably triethanolamine；Composition pH range is 3.0~8.0, preferably 5.0-7.0.
10. by composition described in claim 1-4 any claim, which is characterized in that the combination dosage form include but
It is not limited to lotion, cream, gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811097698.8A CN109125706A (en) | 2018-09-20 | 2018-09-20 | A kind of peptide composition for being effectively improved acne and repairing skin lesion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811097698.8A CN109125706A (en) | 2018-09-20 | 2018-09-20 | A kind of peptide composition for being effectively improved acne and repairing skin lesion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109125706A true CN109125706A (en) | 2019-01-04 |
Family
ID=64815088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811097698.8A Pending CN109125706A (en) | 2018-09-20 | 2018-09-20 | A kind of peptide composition for being effectively improved acne and repairing skin lesion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109125706A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109432396A (en) * | 2019-01-22 | 2019-03-08 | 宇肽生物(东莞)有限公司 | Antibacterial acne-removing active polypeptide |
| CN109771313A (en) * | 2019-04-02 | 2019-05-21 | 靖西市秀美边城农业科技有限公司 | A kind of anti-acne jelly and preparation method thereof |
| CN110115756A (en) * | 2019-05-23 | 2019-08-13 | 中山市粤美医疗生物科技有限公司 | A kind of Essence with antibacterial, anti-acne effect |
| CN110236967A (en) * | 2019-06-21 | 2019-09-17 | 广州艾蓓生物科技有限公司 | A kind of blemish clearing gel |
| CN110292539A (en) * | 2019-08-01 | 2019-10-01 | 深圳市健翔生物制药有限公司 | It is a kind of repair hormone face peptide composition and its application |
| CN110664647A (en) * | 2019-08-15 | 2020-01-10 | 广州欧盛化妆品有限公司 | Skin care product for keeping skin microecological balance and preparation method thereof |
| CN110772446A (en) * | 2019-12-19 | 2020-02-11 | 深圳市维琪医药研发有限公司 | Water-in-oil system skin repair polypeptide composition |
| CN111569145A (en) * | 2020-06-08 | 2020-08-25 | 浙江博纳生物科技有限公司 | Liquid dressing for body surface wound antibacterial repair and preparation method and application thereof |
| CN112402287A (en) * | 2020-11-09 | 2021-02-26 | 浙江湃肽生物有限公司 | Efficient soothing anti-allergy repair polypeptide combination and application thereof |
| CN112587433A (en) * | 2020-12-30 | 2021-04-02 | 宇肽生物(东莞)有限公司 | Polypeptide freeze-dried tablet and preparation method thereof |
| CN112641656A (en) * | 2020-12-30 | 2021-04-13 | 宇肽生物(东莞)有限公司 | Polypeptide microneedle and preparation method thereof |
| CN113208989A (en) * | 2021-03-31 | 2021-08-06 | 湖北神丹健康食品有限公司 | Preserved egg gel paste and preparation method thereof |
| CN114569506A (en) * | 2022-03-07 | 2022-06-03 | 上海铮信生物科技股份有限公司 | Natural active beautifying and acne removing gel composition and preparation method thereof |
| CN114632139A (en) * | 2022-04-02 | 2022-06-17 | 北京双吉制药有限公司 | Erythromycin ointment and preparation method thereof |
| CN115531237A (en) * | 2022-10-12 | 2022-12-30 | 优微（珠海）生物科技有限公司 | Acne-removing repairing composition, acne-removing repairing microneedle patch and preparation method and application of acne-removing repairing microneedle patch |
| CN116019737A (en) * | 2023-03-29 | 2023-04-28 | 天齐(内蒙古)生物科技有限公司 | Preparation process and application of easily absorbable bovine and sheep skin collagen peptide |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102317307A (en) * | 2009-02-16 | 2012-01-11 | 利普泰股份公司 | Peptides used in the treatment and/or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions |
| CN105902435A (en) * | 2016-05-26 | 2016-08-31 | 厦门天绅生物科技有限公司 | Quantum-light wave anti-wrinkle cream and preparation method thereof |
| CN106176274A (en) * | 2016-08-26 | 2016-12-07 | 深圳市维琪医药研发有限公司 | A kind of polypeptide composition with anti-allergic effect |
| CN106236695A (en) * | 2016-06-02 | 2016-12-21 | 哈尔滨源茂达生物技术有限公司 | One peptide species anti-acne repairs essence and preparation method thereof |
| CN107106617A (en) * | 2014-10-31 | 2017-08-29 | 利普泰个人股份有限公司 | Cosmetic and/or pharmaceutical compositions comprising bacterial extracellular products from Pseudoalteromonas antarctica and uses thereof |
| CN108042480A (en) * | 2018-01-12 | 2018-05-18 | 广州赛莱拉干细胞科技股份有限公司 | Mildy wash based on foreign Pseudanabaena sp extract |
| CN108272666A (en) * | 2017-12-29 | 2018-07-13 | 广州赛莱拉干细胞科技股份有限公司 | China fir leaf caulerpa extract surfactant and water charging system |
-
2018
- 2018-09-20 CN CN201811097698.8A patent/CN109125706A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102317307A (en) * | 2009-02-16 | 2012-01-11 | 利普泰股份公司 | Peptides used in the treatment and/or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions |
| CN107106617A (en) * | 2014-10-31 | 2017-08-29 | 利普泰个人股份有限公司 | Cosmetic and/or pharmaceutical compositions comprising bacterial extracellular products from Pseudoalteromonas antarctica and uses thereof |
| CN105902435A (en) * | 2016-05-26 | 2016-08-31 | 厦门天绅生物科技有限公司 | Quantum-light wave anti-wrinkle cream and preparation method thereof |
| CN106236695A (en) * | 2016-06-02 | 2016-12-21 | 哈尔滨源茂达生物技术有限公司 | One peptide species anti-acne repairs essence and preparation method thereof |
| CN106176274A (en) * | 2016-08-26 | 2016-12-07 | 深圳市维琪医药研发有限公司 | A kind of polypeptide composition with anti-allergic effect |
| CN108272666A (en) * | 2017-12-29 | 2018-07-13 | 广州赛莱拉干细胞科技股份有限公司 | China fir leaf caulerpa extract surfactant and water charging system |
| CN108042480A (en) * | 2018-01-12 | 2018-05-18 | 广州赛莱拉干细胞科技股份有限公司 | Mildy wash based on foreign Pseudanabaena sp extract |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109432396A (en) * | 2019-01-22 | 2019-03-08 | 宇肽生物(东莞)有限公司 | Antibacterial acne-removing active polypeptide |
| CN109771313A (en) * | 2019-04-02 | 2019-05-21 | 靖西市秀美边城农业科技有限公司 | A kind of anti-acne jelly and preparation method thereof |
| CN110115756A (en) * | 2019-05-23 | 2019-08-13 | 中山市粤美医疗生物科技有限公司 | A kind of Essence with antibacterial, anti-acne effect |
| CN110236967B (en) * | 2019-06-21 | 2021-10-08 | 广州艾蓓生物科技有限公司 | Acne removing gel |
| CN110236967A (en) * | 2019-06-21 | 2019-09-17 | 广州艾蓓生物科技有限公司 | A kind of blemish clearing gel |
| CN110292539A (en) * | 2019-08-01 | 2019-10-01 | 深圳市健翔生物制药有限公司 | It is a kind of repair hormone face peptide composition and its application |
| CN110664647A (en) * | 2019-08-15 | 2020-01-10 | 广州欧盛化妆品有限公司 | Skin care product for keeping skin microecological balance and preparation method thereof |
| CN110772446A (en) * | 2019-12-19 | 2020-02-11 | 深圳市维琪医药研发有限公司 | Water-in-oil system skin repair polypeptide composition |
| CN110772446B (en) * | 2019-12-19 | 2023-08-22 | 深圳市维琪科技股份有限公司 | Skin repair polypeptide composition of water-in-oil system |
| CN111569145A (en) * | 2020-06-08 | 2020-08-25 | 浙江博纳生物科技有限公司 | Liquid dressing for body surface wound antibacterial repair and preparation method and application thereof |
| CN112402287A (en) * | 2020-11-09 | 2021-02-26 | 浙江湃肽生物有限公司 | Efficient soothing anti-allergy repair polypeptide combination and application thereof |
| CN112641656A (en) * | 2020-12-30 | 2021-04-13 | 宇肽生物(东莞)有限公司 | Polypeptide microneedle and preparation method thereof |
| CN112587433A (en) * | 2020-12-30 | 2021-04-02 | 宇肽生物(东莞)有限公司 | Polypeptide freeze-dried tablet and preparation method thereof |
| CN113208989A (en) * | 2021-03-31 | 2021-08-06 | 湖北神丹健康食品有限公司 | Preserved egg gel paste and preparation method thereof |
| CN113208989B (en) * | 2021-03-31 | 2023-06-27 | 湖北神丹健康食品有限公司 | Preserved egg gel paste and preparation method thereof |
| CN114569506A (en) * | 2022-03-07 | 2022-06-03 | 上海铮信生物科技股份有限公司 | Natural active beautifying and acne removing gel composition and preparation method thereof |
| CN114632139A (en) * | 2022-04-02 | 2022-06-17 | 北京双吉制药有限公司 | Erythromycin ointment and preparation method thereof |
| CN115531237A (en) * | 2022-10-12 | 2022-12-30 | 优微（珠海）生物科技有限公司 | Acne-removing repairing composition, acne-removing repairing microneedle patch and preparation method and application of acne-removing repairing microneedle patch |
| CN115531237B (en) * | 2022-10-12 | 2023-11-03 | 优微（珠海）生物科技有限公司 | Acne-removing repairing composition, acne-removing repairing microneedle patch, and preparation method and application thereof |
| CN116019737A (en) * | 2023-03-29 | 2023-04-28 | 天齐(内蒙古)生物科技有限公司 | Preparation process and application of easily absorbable bovine and sheep skin collagen peptide |
| CN116019737B (en) * | 2023-03-29 | 2023-06-02 | 天齐(内蒙古)生物科技有限公司 | Preparation process and application of easily absorbable bovine and sheep skin collagen peptide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109125706A (en) | A kind of peptide composition for being effectively improved acne and repairing skin lesion | |
| CN109568206B (en) | Special antibacterial composition and lotion for women and preparation method thereof | |
| CN105250189B (en) | A kind of anti-acne maintenance essence cream and preparation method thereof | |
| CN109125107B (en) | Polypeptide composition for effectively improving and repairing facial hormone-dependent dermatitis | |
| CN107519081A (en) | A kind of composition and preparation method that effect is repaired with anti-acne | |
| CN110507672A (en) | A kind of efficient Tiny ecosystem regulator and its application | |
| CN108143639A (en) | A kind of acne eliminating cream and preparation method thereof | |
| AU2014313866B2 (en) | Reaction platform and method for making pollen based materials in combination with beeswax and uses thereof | |
| CN106473944A (en) | A kind of acne-removing composition containing antibacterial peptide and acne eliminating cream | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| CN113995775B (en) | A kind of probiotic foot mask with foot protection effect and preparation method thereof | |
| RU2441660C1 (en) | Method of treatment of subclinical mastitis in lactating cows | |
| JP2023541269A (en) | Probiotic composition for the treatment of acne | |
| CN110354224A (en) | A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa, antipruritic, taste of dispelling | |
| CN108324648A (en) | A kind of composition of anti-acne | |
| RU2367454C1 (en) | Intime hygiene product "femivit" | |
| US10987384B2 (en) | Reaction platform and method for making pollen based materials and uses thereof | |
| KR100980254B1 (en) | Composition for helicobactor pylori bactericide causing gastritis or peptic ulser coprising polylysine and glycerol monolaurate | |
| Kotb et al. | Epidemiological studies of equine mange with special reference to different therapeutic protocols for effective treatment of Chorioptic mange | |
| Glerup et al. | The use of minipigs in non-clinical research | |
| RU2239445C1 (en) | Method for treating subclinical mastitis in lactating cows | |
| WO2019150263A1 (en) | Reaction platform and method for making pollen based materials and uses thereof | |
| RU2698201C1 (en) | Development of antifungal ointment based on salvin | |
| Hind et al. | Topical treatment of feline dermatophytosis | |
| CN110384794A (en) | A kind of ointment for female vulva hickie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |